Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Pegaspargase | |
| Synonyms |
Polyethylene Glycol-L-Asparaginase PEG-asparaginase Polyethylene Glycol L-Asparaginase pegaspargase Pegaspargase Oncaspar-IV PEG-L-Asparaginase L-Asparaginase with Polyethylene Glycol PEG-Asparaginase PEGASPARGASE (Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase PEG-L-Asparaginase (Enzon - Kyowa Hakko) Oncaspar PEGLA |
|
| Definitions |
A complex of polyethylene glycol conjugated with L-asparaginase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle. The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1200 |
|
| Accepted_Therapeutic_Use_For |
Acute lymphoblastic leukemia
|
|
| ALT_DEFINITION |
A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the drug asparaginase that is linked to a substance called PEG, which makes the drug stay in the body longer. Asparaginase is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor.
|
|
| CAS_Registry |
130167-69-0
|
|
| code |
C1200
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc
|
|
| DEFINITION |
A complex of polyethylene glycol conjugated with L-asparaginase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle. The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)
|
|
| Display_Name |
Pegaspargase
|
|
| FDA_UNII_Code |
7D96IR0PPM
|
|
| FULL_SYN |
Polyethylene Glycol-L-Asparaginase PEG-asparaginase Polyethylene Glycol L-Asparaginase pegaspargase Pegaspargase Oncaspar-IV PEG-L-Asparaginase L-Asparaginase with Polyethylene Glycol PEG-Asparaginase PEGASPARGASE (Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase PEG-L-Asparaginase (Enzon - Kyowa Hakko) Oncaspar PEGLA
|
|
| Is_Value_For_GDC_Property | ||
| label |
Pegaspargase
|
|
| Legacy Concept Name |
Pegaspargase
|
|
| Maps_To |
Pegaspargase
|
|
| NCI_Drug_Dictionary_ID |
40312
|
|
| NSC Number |
624239 644954
|
|
| PDQ_Closed_Trial_Search_ID |
40312
|
|
| PDQ_Open_Trial_Search_ID |
40312
|
|
| Preferred_Name |
Pegaspargase
|
|
| prefixIRI |
Thesaurus:C1200
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance
|
|
| UMLS_CUI |
C0071568
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |